EQ 300 mg

EQ 300 mg contains boldenone undecylenate, which is FDA-approved for use in horses as an aid in treating debilitated horses following disease or overwork. In non-medical bodybuilding settings, EQ 300 mg is commonly referenced for lean muscle gains, increased vascularity, and enhanced appetite, though such use falls outside approved indications and the product is not approved for human use.

In veterinary practice, boldenone undecylenate is administered at 3-week intervals. In non-medical bodybuilding contexts, boldenone undecylenate is typically referenced as being administered once or twice weekly to maintain stable blood levels. Because of its long 14-day half-life, some users reference less frequent administration.

In non-medical bodybuilding contexts, post-cycle therapy is commonly recommended after a boldenone undecylenate cycle to help restore endogenous testosterone production. Agents such as Clomid or Nolvadex are commonly referenced for this purpose. Because of boldenone's long half-life, PCT should not begin until 4-5 weeks after the final injection.

Boldenone undecylenate functions as an agonist of the androgen receptor, initiating genomic signaling that promotes anabolism in skeletal muscle and other tissues. It increases nitrogen retention, protein synthesis, appetite, and stimulates the release of erythropoietin in the kidneys. It has strong anabolic properties with low androgenic potency.

Boldenone undecylenate has a long 14-day half-life, meaning effects build slowly. Blood levels approach steady state at weeks 4-6, which is when users typically report noticeable improvements in recovery, appetite, and vascularity. Visible changes in body composition begin to manifest at weeks 8-12 in non-medical contexts.

There is no single compound that is universally best for bulking. Boldenone undecylenate is commonly referenced in bodybuilding contexts for lean, water-free muscle gains and increased vascularity, but individual response and goals vary. Many non-medical cycles combine boldenone with a testosterone base such as Cypionate 250 rather than using it alone.

EQ 300 mg contains boldenone undecylenate, while Deca 300 contains nandrolone decanoate. Boldenone is a testosterone derivative with a double bond between carbon atoms 1 and 2, while nandrolone is a 19-nor compound. Both are long-acting injectable anabolic steroids, but they have different receptor activity profiles and side effect characteristics.

The primary difference is concentration. EQ 300 mg provides 300 mg of boldenone undecylenate per mL, while EQ 500 provides 500 mg/mL. Higher-concentration products allow for reduced injection volume at equivalent doses but are typically referenced for more experienced users.

A milligram amount cannot be classified as appropriate or excessive without considering the specific context, individual response, and other factors. In non-medical bodybuilding contexts, boldenone undecylenate is commonly referenced in the 400–600 mg per week range, with some sources citing standard dosage ranges of 400-1000 mg per week. Such use falls outside approved indications.

It is also important to distinguish a dose in milligrams from a product's concentration in mg/mL. EQ 300 mg is labeled at 300 mg/mL; that concentration does not by itself specify how much should be administered.

EQ 300 mg is labeled at 300 mg of boldenone undecylenate per mL. It is supplied in a 10 mL vial, giving 3,000 mg of total labeled boldenone undecylenate content per vial.

Yes. A published laboratory report dated November 20, 2025 measured EQ 300 mg at 315.64 mg, equivalent to 105.21% of its 300 mg/mL label claim.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

The published laboratory report for EQ 300 mg references batch BUBG9, tested on November 20, 2025. The measured result for that sample was 315.64 mg.